TESTOSTERONES PRIOR AUTHORIZATION REQUEST FORM



OptumRx P.O. Box 25184 Santa Ana, CA, 92799 Phone: (800) 310-6826 Fax: (866) 940-7328





			Community I
Today's Date			
Note: This form must be complete	d by the prescrib	ing provider.	
All sections	must be complet	ed or the request	will be returned
Patient's Medicaid #		Date of Birth	
Patient's Name		Prescriber's Nan	ne
Prescriber's IN License #		Specialty	
Prescriber's NPI#		Prescriber's Sigr	nature
Return Fax #		Return Phone #	
Check box if requesting retro-active PA		Date(s) of servic retro-active eligit	e requested for pility (if applicable):
Note: Submit PA requests for retroactive of eligibility timelines) with dates of service proof service 30 calendar days or less and go	rior to 30 calendar d		
Requested Medication	Strength	Quantity	Dosage Regimen
2. For ALL indications: Provider attests that member has Breast cancer in a memb Pregnancy Prostate cancer If no, please specify contrain	elayed puberty one level ≤ 350 ng. none of the follow er assigned male	/dL within the past ving contraindication at birth	
Reauthorization: 1. Total testosterone level is ≤ 1000 i	ng/dL within the pa	ast 6 months (Docur	mentation is required)
Provider attests that member remathe contraindication(s) listed unde			ting that they have not developed any of ☐ No

If no , please specify contraindication and medical rationale for use:
TESTOSTERONE ENANTHATE
Initial Authorization:
1. Please select one of the following:
☐ Member has a diagnosis of delayed puberty
Has the member had a previous trial and failure of ALL preferred injectable testosterone agents
(reference PA criteria)? ☐ Yes ☐ No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
 Member has a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required) Has the member had a previous trial and failure of ALL preferred injectable testosterone agents (reference PA criteria)? ☐ Yes ☐ No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
☐ Member needs medication for palliative treatment of metastatic breast cancer
 2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: Yes No Breast cancer in a member assigned male at birth Pregnancy Prostate cancer
If no , please specify contraindication and medical rationale for use:
Reauthorization:
1. Total testosterone level is \leq 1000 ng/dL within the past 6 months (Documentation is required) \square Yes \square No
2. Has the member had a previous trial and failure of at least ONE preferred injectable testosterone agent (not required for palliative treatment of breast cancer) [reference PA criteria]? Yes No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:

If no , please specify contraindication and medical rationale for use:

AVEED, TESTOPEL PELLET, XYSOTED	
Initial Authorization: 1. Please select one of the following: Member has a diagnosis of delayed puberty Has the member had a previous trial and failure of ALL preferred injectable testosterone agents (reference PA criteria)? Yes No If no, please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:	
 Member has a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required) Has the member had a previous trial and failure of ALL preferred injectable testosterone agents (reference PA criteria)? ☐ Yes ☐ No If no, please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents: 	
 2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: Yes No Breast cancer in a member assigned male at birth Hypogonadal conditions not associated with structural or genetic etiologies (Xyosted ONLY) Pregnancy Prostate cancer If no, please specify contraindication and medical rationale for use: 	
ii no, please specify contraindication and medical rationale for use.	
Reauthorization:	
1. Total testosterone level is ≤1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No	
2. Has the member had a previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria)? ☐ Yes ☐ No	
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:	
3. Provider attests that member remains a candidate for treatment, indicating that they have not developed any the contraindication(s) listed under initial authorization above ☐ Yes ☐ No	/ of
If no , please specify contraindication and medical rationale for use:	

ANDRODERM, TESTOSTERONE 1% (25 MG)/ 2.5 GM GEL PACKETS, TESTOSTERONE 1% (12.5 MG)/ACT GEL PUMP, TESTOSTERONE 1.62% (20.25 MG)/ACT METERED PUMP GEL, TESTIM 1% (50 MG)/5 GM GEL TUBES

nitial Authorization:	
 Please select one of the following: Member is 16 years of age or older, has a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required), and is requesting to use topical testosterone within the established quantity limits 	
Requested dose:	
Member is 16 years of age or older, has a total testosterone level ≤ 400 ng/dL while on topical testosterone therapy (Documentation is required) and is requesting to exceed established quantity limits	
Requested dose:	
Member has utilized ≥ 14 days of topical testosterone therapy: ☐ Yes ☐ No	
Name of medication:	
Dose:	
Start and End date:	
If no , please provide medical justification as to why member is requesting a dose beyond established quantity limits:	
2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No • Breast cancer in a member assigned male at birth • Pregnancy • Prostate cancer If no, please specify contraindication and medical rationale for use:	
Reauthorization:	_
1. Total testosterone level is ≤ 1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No	
2. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No	
If no , please specify contraindication and medical rationale for use:	
Note: dose requested for reauthorization should not exceed established quantity limits unless member nistorically has been approved to exceed the established quantity limits Requested dose:	

NATESTO, TESTOSTERONE 1% (50 MG)/5 GM GEL PACKETS/TUBES, TESTOSTERONE 1.62% (40.5 MG)/2.5 GM GEL PACKETS, TESTOSTERONE 1.62% (20.25 MG)/1.25 GM GEL PACKETS, TESTOSTERONE 2% (10 MG)/ACT METERED PUMP, TESTOSTERONE 30 MG/ACT SOLUTION, VOGELXO 1% (50 MG)/5 GM GEL PACKETS, VOGELXO 1% (12.5 MG)/ACT GEL PUMP

Initial Authorization: 1. Please select one of the following:
 Member is 16 years of age or older, has a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required), and is requesting to use topical testosterone within the established quantity limits
Requested dose:
Requested dose:
Member has utilized ≥ 14 days of topical testosterone therapy: ☐ Yes ☐ No Name of medication:
Dose:
Start and End date:
If no , please provide medical justification as to why member is requesting a dose beyond established quantity limits:
2. Previous trial and failure of ALL preferred topical testosterone agents (reference PA criteria) Yes No If no, please provide medical justification for use of requested agent over ALL preferred topical testosterone agents:
3. For ALL indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No • Breast cancer in a member assigned male at birth • Pregnancy • Prostate cancer
If no , please specify contraindication and medical rationale for use:
Reauthorization: 1. Total testosterone level is ≤1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No 2. Previous trial and failure of at least ONE preferred topical testosterone agent ☐ Yes ☐ No

If no , please provide medical justification for use of requested agent over ALL preferred topical testosterone agents:
3. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above ☐ Yes ☐ No If no , please specify contraindication and medical rationale for use:
Note: dose requested for reauthorization should not exceed established quantity limits unless member historically has been approved to exceed the established quantity limits Requested dose:
DANOCRINE (DANAZOL):
Initial Authorization (approval up to 6 months):
1. Member diagnosis(es):
Note: Approvable diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, discoid lupus erythematosus, endometriosis, fibrocystic breast disease, myelosclerosis with myeloid metaplasia
 2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No Active or history of thrombosis or thromboembolic disease Androgen-dependent tumor
 Cardiac disease Porphyria Pregnancy or breast-feeding Severe hepatic disease
 Severe renal disease Undiagnosed genital bleeding
If no , please specify contraindication and medical rationale for use:
Reauthorization (approval up to 6 months):
Documentation from prescriber indicating continued benefit from the medication without significant adverse events ☐ Yes ☐ No
2. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above ☐ Yes ☐ No
If no , please specify contraindication and medical rationale for use:

JATENZO (TESTOSTERONE UNDECANOATE):
Initial Authorization:1. Member is 18 years of age or older and is requesting to use oral testosterone within the established quantity limits
Requested dose: Yes No
2. Member has a diagnosis of hypogonadism with a total testosterone level \leq 350 ng/dL within the past 3 months (Documentation is required) \square Yes \square No
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) ☐ Yes ☐ No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
4. For ALL indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No
 Breast cancer in a member assigned male at birth Hypogonadal conditions not associated with structural or genetic etiologies Pregnancy Prostate cancer
If no , please specify contraindication and medical rationale for use:
Reauthorization: 1. Total testosterone level is ≤ 1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No
2. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No
If no , please specify contraindication and medical rationale for use:
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) ☐ Yes ☐ No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
Note: dose requested for reauthorization should not exceed established quantity limits Requested dose:

Initial Authorization (approval up to 6 months):
initial Authorization (approval up to 6 months).
 1. Please select one of the following: Member has a diagnosis of cryptorchidism Member has a diagnosis of delayed puberty Member has a diagnosis of hypogonadism (primary or hypogonadotropic) with a total testosterone ≤ 350 ng/dL within the past 3 months (Documentation is required) Member needs medication for palliative treatment of metastatic breast cancer
2. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) \square Yes \square No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
3. For ALL indications:
 Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No Breast cancer in a member assigned male at birth Pregnancy Prostate cancer
If no , please specify contraindication and medical rationale for use:
4. Dose requested of methyltestosterone is within the established quantity limits
Requested dose: Yes No
Describe direction (approved up to Carenthe)
Reauthorization (approval up to 6 months): 1. Please select one of the following:
2. For ALL indications: Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above ☐ Yes ☐ No
If no , please specify contraindication and medical rationale for use:
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) ☐ Yes ☐ No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:

Note: dose requested for reauthorization should not exceed established quantity limits
Requested dose:
Initial Authorization: 1. Member is 18 years of age or older and is requesting to use oral testosterone within the established quantity limits
Requested dose: Yes No
2. Member has a diagnosis of hypogonadism and a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required) ☐ Yes ☐ No
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) \square Yes \square No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
 4. For ALL indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No ■ Breast cancer ■ Hypogonadal conditions not associated with structural or genetic etiologies ■ Pregnancy ■ Prostate cancer
If no , please specify contraindication and medical rationale for use:
Reauthorization:
1. Total testosterone level is ≤ 1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No
2. Prescriber attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No
If no , please specify contraindication and medical rationale for use:
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) ☐ Yes ☐ No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
Note: dose requested for reauthorization should not exceed established quantity limits
Requested dose:

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.